BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 30298903)

  • 1. Treatment of mycosis fungoides and Sézary syndrome with romidepsin: a series of 32 cases from the French Study Group for Cutaneous Lymphoma.
    Deschamps O; Ram-Wolff C; Beylot-Barry M; Grange F; Skowron F; Dereure O; Boulinguez S; Aubin F; Ingen-Housz-Oro S; Bagot M;
    Br J Dermatol; 2019 Feb; 180(2):423-424. PubMed ID: 30298903
    [No Abstract]   [Full Text] [Related]  

  • 2. Romidepsin for the treatment of relapsed/refractory cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome): Use in a community setting.
    Reddy SA
    Crit Rev Oncol Hematol; 2016 Oct; 106():99-107. PubMed ID: 27637355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sézary Syndrome.
    Zic JA
    Dermatol Clin; 2015 Oct; 33(4):765-76. PubMed ID: 26433848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sezary Syndrome.
    Querfeld C; Zain J; Rosen ST
    Cancer Treat Res; 2019; 176():225-248. PubMed ID: 30596221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic chemotherapy for the treatment of mycosis fungoides and Sézary syndrome.
    Kuzel TM
    Dermatol Ther; 2003; 16(4):355-61. PubMed ID: 14686979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of advanced mycosis fungoides and Sézary syndrome with continuous infusions of methotrexate followed by fluorouracil and leucovorin rescue.
    Schappell DL; Alper JC; McDonald CJ
    Arch Dermatol; 1995 Mar; 131(3):307-13. PubMed ID: 7887660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of cutaneous lymphoma international prognostic index (CLIPI) for mycosis fungoides and Sézary syndrome.
    Danish HH; Liu S; Jhaveri J; Flowers CR; Lechowicz MJ; Esiashvili N; Khan MK
    Leuk Lymphoma; 2016 Dec; 57(12):2813-2819. PubMed ID: 27104864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides.
    Foss F; Duvic M; Lerner A; Waksman J; Whittaker S
    Clin Lymphoma Myeloma Leuk; 2016 Nov; 16(11):637-643. PubMed ID: 27637428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alemtuzumab induced complete remission of romidepsin-refractory large cell transformation of mycosis fungoides.
    Kwong YL
    Ann Hematol; 2014 Apr; 93(4):713-4. PubMed ID: 23934231
    [No Abstract]   [Full Text] [Related]  

  • 10. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome.
    Benton EC; Crichton S; Talpur R; Agar NS; Fields PA; Wedgeworth E; Mitchell TJ; Cox M; Ferreira S; Liu P; Robson A; Calonje E; Stefanato CM; Wilkins B; Scarisbrick J; Wain EM; Child F; Morris S; Duvic M; Whittaker SJ
    Eur J Cancer; 2013 Sep; 49(13):2859-68. PubMed ID: 23735705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Romidepsin and total skin electron beam therapy in advanced stage mycosis fungoides and Sézary syndrome.
    Jothishankar B; Almazan T; Kim Y; Liauw S; Smith S; Kline J; Abdulla F
    Br J Haematol; 2019 Jul; 186(2):377-379. PubMed ID: 30937886
    [No Abstract]   [Full Text] [Related]  

  • 12. Total body-surface area as a new prognostic variable in mycosis fungoides and Sézary syndrome.
    Novelli S; García-Muret P; Mozos A; Sierra J; Briones J
    Leuk Lymphoma; 2016 May; 57(5):1060-6. PubMed ID: 27096891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mycosis fungoides and total skin electron beam radiation.
    Jones GW; Wilson LD
    Blood; 1997 Apr; 89(8):3062-4. PubMed ID: 9108429
    [No Abstract]   [Full Text] [Related]  

  • 14. Oral retinoids in mycosis fungoides and Sézary syndrome: a comparison of isotretinoin and etretinate. A study from the Scandinavian Mycosis Fungoides Group.
    Molin L; Thomsen K; Volden G; Aronsson A; Hammar H; Hellbe L; Wantzin GL; Roupe G
    Acta Derm Venereol; 1987; 67(3):232-6. PubMed ID: 2442936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New and established treatment options for mycosis fungoides and Sézary syndrome - an update.
    Dugas-Breit S; Schulze HJ; Hallermann C
    J Dtsch Dermatol Ges; 2014 Jul; 12(7):561-9. PubMed ID: 24889480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. State of the art therapy of mycosis fungoides and Sézary syndrome.
    Kemme DJ; Bunn PA
    Oncology (Williston Park); 1992 Feb; 6(2):31-42; discussion 44, 47-8. PubMed ID: 1532501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycosis fungoides and the Sézary syndrome.
    Foss F
    Curr Opin Oncol; 2004 Sep; 16(5):421-8. PubMed ID: 15314509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: development of extracutaneous lymphoma in 6 patients.
    Bouwhuis SA; Davis MD; el-Azhary RA; McEvoy MT; Gibson LE; Knudsen JM; Kist JM; Pittelkow MR
    J Am Acad Dermatol; 2005 Jun; 52(6):991-6. PubMed ID: 15928617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limited effect of chemotherapy in cutaneous lymphoma.
    Vermeer MH; Willemze R
    Blood; 2015 Jan; 125(1):4-5. PubMed ID: 25554742
    [No Abstract]   [Full Text] [Related]  

  • 20. Pentostatin plus cyclophosphamide and bexarotene is an effective and safe combination in patients with mycosis fungoides/Sezary syndrome.
    Calderon Cabrera C; de la Cruz Vicente F; Marín-Niebla A; Carrillo Cruz E; Rios Herranz E; Espigado Tocino I; Prats Martín C; Falantes JF; Martino Galiana ML; Perez-Simón JA
    Br J Haematol; 2013 Jul; 162(1):130-2. PubMed ID: 23581433
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.